The Tiny Biotech That Might Dethrone Novartis in Leukemia
Enliven Therapeutics posted leukemia drug data that has every analyst on Wall Street screaming Buy. The tiny biotech's CML pill is eyeing territory that Novartis has owned for two decades, and the numbers suggest it might actually belong there.
Six approved drugs already treat chronic myeloid leukemia. Novartis alone makes three of them. So when a five-year-old company with zero approved products and a roughly $1.1 billion market cap walks into that arena, you'd expect the Street to yawn.
Instead, the vast majority of analysts covering Enliven Therapeutics rate it a Buy. And after the company's latest clinical data, a few of them think the stock could more than double.
The Drug That Has Wall Street's Attention
Enliven's lead candidate is ELVN-001, a pill designed to block a protein called BCR-ABL1. Think of BCR-ABL1 as a broken switch inside white blood cells: it gets stuck in the "on" position and tells cells to multiply uncontrollably. That's CML in a nutshell.
There are already drugs that flip that switch off. Imatinib (Novartis's legendary Gleevec) was the first, and it changed CML from a death sentence into a manageable disease. But many patients develop resistance over time, like bacteria evolving past an antibiotic. Newer drugs handle some of those resistant cases, but they often come with serious side effects: blood vessel damage, dangerous drops in blood cell counts, fluid buildup in the lungs.
ELVN-001 is designed to thread a very specific needle. It targets the same broken switch but binds it in a unique way, folding a section of the protein (called the P-loop) into an unusual position. That gives it coverage against tough resistance mutations, including the notorious T315I variant that stumps many older drugs.
The Numbers That Matter
Enliven presented updated Phase 1b data from its ENABLE trial at the European Hematology Association meeting, and the results caught eyes.
In the overall Phase 1b group, 47% of patients hit major molecular response (MMR) by 24 weeks. MMR is the gold standard measurement: it means the cancer's genetic signal has dropped by at least a thousand-fold. At the specific dose Enliven is betting on (80 mg once daily), cumulative MMR reached 61% (which includes patients who maintained pre-existing MMR), while 48% newly achieved MMR.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
For context, these weren't easy patients. Many had already failed multiple prior treatments, including third-generation drugs like ponatinib and Novartis's newer allosteric inhibitor, asciminib (brand name Scemblix). Among patients who were resistant to their last therapy, 41% still reached MMR by 24 weeks.
The depth of response was also notable. About 30% of patients on the 80 mg dose achieved deep molecular response (DMR) at 24 weeks, meaning their cancer signal dropped even further. In a heavily pretreated population, that's a strong signal.
The Safety Story Is Just as Important
In CML, patients often take their drug for years, sometimes decades. So tolerability isn't a nice-to-have; it's everything. A drug that works brilliantly but causes heart attacks or severe blood problems won't win.
This is where ELVN-001 looks particularly compelling. Only 3.4% of patients needed dose reductions and just 4.6% discontinued due to side effects. Severe non-blood-related side effects were rare at 2.3%. The company reported no arterial blockage events and no cardiovascular toxicity signals, which is a meaningful distinction from ponatinib and nilotinib, both known for vascular risks.
Blood-related side effects (low platelets, low white cells) did occur but at manageable rates: 6% for severe thrombocytopenia and 5.7% for severe neutropenia. No maximum tolerated dose was reached, suggesting there's still room if needed.
Why Novartis Should Be Watching
Novartis owns the CML market like few companies own anything in oncology. Gleevec built the foundation. Nilotinib added a second-generation option. And asciminib brought a genuinely new mechanism (it binds a completely different spot on the protein) that earned front-line approval in some countries.
But asciminib has a vulnerability: patients can develop mutations that specifically resist its unique binding approach. ELVN-001 was designed to cover exactly those mutations. That creates an interesting dynamic where the two drugs could complement each other rather than compete head-to-head. Stifel's analysts made this point explicitly, initiating coverage with a Buy and a $60 price target, framing ELVN-001 as a complementary therapy to Scemblix rather than a replacement.
Guggenheim went further, slapping an $80 target on the stock and calling ELVN-001 a potential best-in-class oral BCR-ABL inhibitor. Mizuho raised its target to $62.
The Company Behind the Drug
Enliven was founded in 2019 by Sam Kintz and went public through a reverse merger with Imara in February 2023. That deal came with a $164.5 million financing round, leaving the company with about $300 million in cash.
The founding team's chemists have serious pedigree: they were primary or co-inventors of clinical candidates that became approved drugs like Tukysa. Enliven also has a second program, ELVN-002, a selective HER2 inhibitor for solid tumors currently in Phase 1 trials.
But ELVN-001 is the main event. The company has reached alignment with the FDA on Phase 3 trial design, and it plans to launch its pivotal study (called ENABLE-2) in the second half of 2026. That's the real catalyst: moving from promising early data into the kind of trial that could support an actual approval.
The Stock Already Ran. Is It Too Late?
Enliven shares gained about 63% in 2024, though they have pulled back modestly in 2025. At current levels, the market cap hovers around $1.1 billion, which is rich for a company with no revenue and a Phase 1 asset.
Analysts argue the market isn't fully pricing in the quality of the data or the size of the CML opportunity.
The bear case is straightforward: this is still early-stage data in a relatively small number of patients. Phase 3 trials can disappoint. And the CML market, while meaningful, is not enormous compared to solid tumor indications.
The bull case is that ELVN-001's combination of efficacy, safety, and mutation coverage looks genuinely differentiated in a space where patients cycle through multiple drugs over their lifetimes. If the Phase 3 confirms what Phase 1 is showing, Enliven won't just be competing with Novartis. It'll be sitting at the same table.
For a company that didn't exist six years ago, that's not a bad seat to have.
Clinical & Regulatory
4 min read
Sanofi's Plan B Just Lost Its Plan B
Sanofi just halted another late-stage trial, and it's not the first pipeline disappointment this year. With Dupixent's patents expiring around 2031 and its top successor underwhelming Wall Street, the pressure to find a Plan D is getting very real.
